---
id: "claim-openevidence-scale"
type: "claim"
source_timestamps: ["§ Intro"]
tags: ["healthcare", "ai-adoption"]
related: ["entity-openevidence"]
confidence: "high"
testable: true
external_validation: "entity-real-metrics-vendor-reported"
sources: ["geo"]
sourceVaultSlug: "hbr-seg-geo"
originDay: 3
articleStem: "hbr-tier1-01-gen-ai-b2b-buying"
sourceUrl: "https://hbr.org/2026/06/how-gen-ai-is-disrupting-b2b-buying-decisions"
sourceTitle: "How Gen AI is Disrupting B2B Buying Decisions"
---
# Clinical AI assistants have achieved durable workflow integration

[[entity-openevidence]], a clinical decision-support AI assistant, is used **daily by more than 40% of U.S. physicians**. It handled **over 20 million physician queries in January 2026** — a *sevenfold* increase from roughly **2.6 million in December 2024** — signalling durable workflow integration rather than mere experimentation. This is the opening proof point that AI-mediated professional decision-making is real and sticky, not hype.

**Confidence & external validation:** OpenEvidence's existence and positioning as an evidence-based clinical decision-support AI (originated at Brown University, spun out commercially) are well supported. However, the enrichment overlay could **not** independently verify `>40% daily`, `20M queries (Jan 2026)`, or `2.6M (Dec 2024)`. **Treat the penetration and query-volume numbers as vendor-reported adoption claims**, not peer-reviewed or regulator-reported statistics.